Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 414

1.

Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' reply.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 Jun 28. pii: S1590-8658(18)30801-6. doi: 10.1016/j.dld.2018.06.014. [Epub ahead of print] No abstract available.

PMID:
30005959
2.

Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P; Thésaurus National de Cancérologie Digestive (TNCD).

Dig Liver Dis. 2018 Jun 6. pii: S1590-8658(18)30722-9. doi: 10.1016/j.dld.2018.04.025. [Epub ahead of print] Review.

PMID:
29886081
3.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF; for FFCD investigators.

Eur J Cancer. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26.

4.

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Mar 1:300891618763215. doi: 10.1177/0300891618763215. [Epub ahead of print]

PMID:
29714649
5.

MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach.

Schmoll HJ, Arnold D, de Gramont A, Ducreux M, Grothey A, O'Dwyer PJ, Van Cutsem E, Hermann F, Bosanac I, Bendahmane B, Mancao C, Tabernero J.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1197-1204. doi: 10.1007/s00432-018-2632-6. Epub 2018 Apr 11.

PMID:
29644408
6.

Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology.

Texier M, Rotolo F, Ducreux M, Bouché O, Pignon JP, Michiels S.

Comput Math Methods Med. 2018 Jan 11;2018:1672176. doi: 10.1155/2018/1672176. eCollection 2018.

7.

[Metastatic colorectal cancer: To stop or not to stop?]

Artru P, Bennouna J, Lievre A, Ducreux M, Lledo G.

Bull Cancer. 2018 Apr;105(4):408-414. doi: 10.1016/j.bulcan.2017.12.010. Epub 2018 Feb 22. Review. French.

PMID:
29477654
8.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
9.

Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas.

Zajac O, Raingeaud J, Libanje F, Lefebvre C, Sabino D, Martins I, Roy P, Benatar C, Canet-Jourdan C, Azorin P, Polrot M, Gonin P, Benbarche S, Souquere S, Pierron G, Nowak D, Bigot L, Ducreux M, Malka D, Lobry C, Scoazec JY, Eveno C, Pocard M, Perfettini JL, Elias D, Dartigues P, Goéré D, Jaulin F.

Nat Cell Biol. 2018 Mar;20(3):296-306. doi: 10.1038/s41556-017-0027-6. Epub 2018 Feb 5.

PMID:
29403038
10.

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza RA, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 May;50(5):507-512. doi: 10.1016/j.dld.2017.12.029. Epub 2018 Jan 8.

PMID:
29396127
11.

Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial.

Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, André T, Ducreux M, Gornet JM, Goujon G, Aparicio T, Taieb J, Bachet JB, Hemery F, Retbi A, Mons M, Flicoteaux R, Rhein B, Baron S, Cherrak I, Rufat P, Le Corvoisier P, de'Angelis N, Natella PA, Maoulida H, Tournigand C, Durand Zaleski I, Bastuji-Garin S.

Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031.

12.

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, Ammari S, Lacroix L, Ducreux M, Scoazec JY, Malka D, Paci A, Hollebecque A.

Eur J Cancer. 2018 Feb;90:83-91. doi: 10.1016/j.ejca.2017.11.024. Epub 2018 Jan 4.

PMID:
29274619
13.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: Eur J Cancer. 2018 Feb 14;:.

PMID:
29145038
14.

Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona.

Baraniskin A, Van Laethem JL, Wyrwicz L, Guller U, Wasan HS, Matysiak-Budnik T, Gruenberger T, Ducreux M, Carneiro F, Van Cutsem E, Seufferlein T, Schmiegel W.

Eur J Cancer. 2017 Nov;86:305-317. doi: 10.1016/j.ejca.2017.09.021. Epub 2017 Oct 21. Review.

PMID:
29065378
15.

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer-A definite conclusion?

Ducreux M, Österlund P, Pignon JP.

Semin Oncol. 2017 Apr;44(2):129-131. doi: 10.1053/j.seminoncol.2017.07.002. Epub 2017 Jul 29. No abstract available.

PMID:
28923210
16.

Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.

Le Roy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, Benhaim L, Malka D, Ducreux M, Elias D, Goéré D.

Ann Surg Oncol. 2017 Nov;24(12):3640-3646. doi: 10.1245/s10434-017-6033-x. Epub 2017 Aug 28.

PMID:
28849389
17.

Are we reproducible in measurement of NET liver metastasis?

Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D, Goere D, Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E.

Dig Liver Dis. 2017 Oct;49(10):1121-1127. doi: 10.1016/j.dld.2017.05.015. Epub 2017 Jun 28.

PMID:
28844707
18.

Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).

Lévi F, Karaboué A, Saffroy R, Desterke C, Boige V, Smith D, Hebbar M, Innominato P, Taieb J, Carvalho C, Guimbaud R, Focan C, Bouchahda M, Adam R, Ducreux M, Milano G, Lemoine A.

Br J Cancer. 2017 Sep 26;117(7):965-973. doi: 10.1038/bjc.2017.278. Epub 2017 Aug 17.

PMID:
28817838
19.

Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC.

Roy P, Canet-Jourdan C, Annereau M, Zajac O, Gelli M, Broutin S, Mercier L, Paci A, Lemare F, Ducreux M, Elias D, Malka D, Boige V, Goéré D, Jaulin F.

Int J Pharm. 2017 Oct 5;531(1):143-152. doi: 10.1016/j.ijpharm.2017.07.084. Epub 2017 Aug 11.

PMID:
28803938
20.

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D, Ferté C.

Eur J Cancer. 2017 Aug;81:161-173. doi: 10.1016/j.ejca.2017.05.006. Epub 2017 Jun 17. Review.

PMID:
28628842
21.

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP).

Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L, Ducreux M, Bouché O.

Dig Liver Dis. 2017 Aug;49(8):831-840. doi: 10.1016/j.dld.2017.05.011. Epub 2017 May 23. Review.

PMID:
28610905
22.

3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.

Lutz MP, Zalcberg JR, Ducreux M, Aust D, Bruno MJ, Büchler MW, Delpero JR, Gloor B, Glynne-Jones R, Hartwig W, Huguet F, Laurent-Puig P, Lordick F, Maisonneuve P, Mayerle J, Martignoni M, Neoptolemos J, Rhim AD, Schmied BM, Seufferlein T, Werner J, van Laethem JL, Otto F.

Eur J Cancer. 2017 Jul;79:41-49. doi: 10.1016/j.ejca.2017.03.022. Epub 2017 Apr 29.

23.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J.

Eur J Cancer. 2017 Jul;79:15-22. doi: 10.1016/j.ejca.2017.03.036. Epub 2017 Apr 26.

PMID:
28456090
24.

Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.

Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, Poston G, Bechstein W, Lentz MA, Mauer M, Folprecht G, Van Cutsem E, Ducreux M, Nordlinger B; European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG).

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx015.

25.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T.

Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.

PMID:
28292641
26.

Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).

Bennouna J, Phelip JM, André T, Asselain B, Sébastien Koné, Ducreux M.

Clin Colorectal Cancer. 2017 Jun;16(2):129-140.e4. doi: 10.1016/j.clcc.2016.07.013. Epub 2016 Aug 9.

PMID:
28277294
27.

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY, Baudin E, Planchard D.

Eur J Cancer. 2017 Apr;75:259-267. doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27.

PMID:
28242503
28.

Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?

Ducreux M.

Lancet Oncol. 2017 Apr;18(4):426-428. doi: 10.1016/S1470-2045(17)30159-6. Epub 2017 Feb 24. No abstract available.

PMID:
28238598
29.

The role of image-guided therapy in the management of colorectal cancer metastatic disease.

de Baere T, Tselikas L, Yevich S, Boige V, Deschamps F, Ducreux M, Goere D, Nguyen F, Malka D.

Eur J Cancer. 2017 Apr;75:231-242. doi: 10.1016/j.ejca.2017.01.010. Epub 2017 Feb 24. Review.

PMID:
28237869
30.

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).

Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S, Guimbaud R, Niccoli P, Legoux JL, Mitry E, Rohmer V, Ruszniewski P, Walter T, Ducreux M, Couvelard A, Scoazec JY, Ramond-Roquin A, Caroli-Bosc FX, Hentic O.

Neuroendocrinology. 2018;106(1):38-46. doi: 10.1159/000457955. Epub 2017 Feb 3.

31.

Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG.

Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, Schrauwen S, Yoshikawa T, Roviello F, Tokunaga M, Boku N, Ducreux M, Terashima M, Lordick F; EORTC GITCG Group and JCOG SCGC Group.

Gastric Cancer. 2017 Sep;20(5):904-912. doi: 10.1007/s10120-017-0696-7. Epub 2017 Feb 1.

PMID:
28150070
32.

Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation.

Schernberg A, Moureau-Zabotto L, Rivin Del Campo E, Escande A, Ducreux M, Nguyen F, Goere D, Chargari C, Deutsch E.

Oncotarget. 2017 Feb 14;8(7):11579-11588. doi: 10.18632/oncotarget.14584.

33.

Leukocytosis and neutrophilia predicts outcome in anal cancer.

Schernberg A, Escande A, Rivin Del Campo E, Ducreux M, Nguyen F, Goere D, Chargari C, Deutsch E.

Radiother Oncol. 2017 Jan;122(1):137-145. doi: 10.1016/j.radonc.2016.12.009. Epub 2016 Dec 24.

PMID:
28024835
34.

Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).

de Baere T, Tselikas L, Boige V, Ducreux M, Malka D, Goéré D, Benahim E, Deschamps F.

Bull Cancer. 2017 May;104(5):402-406. doi: 10.1016/j.bulcan.2016.10.025. Epub 2016 Dec 16. Review.

PMID:
27993355
35.

Imaging of neuroendocrine tumors of the pancreas.

Dromain C, Déandréis D, Scoazec JY, Goere D, Ducreux M, Baudin E, Tselikas L.

Diagn Interv Imaging. 2016 Dec;97(12):1241-1257. doi: 10.1016/j.diii.2016.07.012. Epub 2016 Nov 18. Review.

36.

Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial.

Ducreux M, Bennouna J, Adenis A, Conroy T, Lièvre A, Portales F, Jeanes J, Li L, Romano A.

Cancer Chemother Pharmacol. 2017 Jan;79(1):9-16. doi: 10.1007/s00280-016-3193-5. Epub 2016 Nov 19.

PMID:
27866244
37.

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.

Loulergue P, Merad M, Coriat R, Ducreux M, Planchard D, Boige V, Le Cesne A, Gregory TM, Poinsignon V, Paci A, Mir O.

Invest New Drugs. 2017 Apr;35(2):247-249. doi: 10.1007/s10637-016-0405-0. Epub 2016 Nov 12.

PMID:
27838867
38.

Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?

Ducreux M, Pignon JP.

Eur J Cancer. 2016 Dec;69:178-179. doi: 10.1016/j.ejca.2016.10.001. Epub 2016 Nov 10. No abstract available.

PMID:
27835821
39.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

Van Laethem JL, Carneiro F, Ducreux M, Messman H, Lordick F, Ilson DH, Allum WH, Haustermans K, Lepage C, Matysiak-Budnik T, Cats A, Schmiegel W, Cervantes A, Van Cutsem E, Rougier P, Seufferlein T.

Dig Liver Dis. 2016 Nov;48(11):1283-1289. doi: 10.1016/j.dld.2016.08.112. Epub 2016 Aug 20.

PMID:
27590840
40.

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.

Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F; ARTBC International.

Eur J Cancer. 2016 Nov;68:163-172. doi: 10.1016/j.ejca.2016.09.011. Epub 2016 Oct 18.

PMID:
27768923
41.

Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24].

Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F.

Eur J Cancer. 2016 Nov;68:208-209. doi: 10.1016/j.ejca.2016.08.017. Epub 2016 Oct 4. No abstract available.

42.

Long-term survival after aggressive treatment of relapsed serosal or distant pseudomyxoma peritonei.

Delhorme JB, Honoré C, Benhaim L, Dumont F, Dartigues P, Dromain C, Ducreux M, Elias D, Goéré D.

Eur J Surg Oncol. 2017 Jan;43(1):159-167. doi: 10.1016/j.ejso.2016.08.021. Epub 2016 Sep 2.

PMID:
27646440
43.

Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals.

Tlemsani C, Mir O, Psimaras D, Vano YA, Ducreux M, Escudier B, Rousseau B, Loirat D, Ceccaldi B, André T, Goldwasser F, Ricard D.

Eur J Cancer. 2016 Oct;66:75-82. doi: 10.1016/j.ejca.2016.07.008. Epub 2016 Aug 15.

PMID:
27529757
44.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D.

Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.

PMID:
27380959
45.

Treatment sequence of synchronously (liver) metastasized colon cancer.

Gruenberger T, Beets G, Van Laethem JL, Rougier P, Cervantes A, Douillard JY, Figueras J, Gruenberger B, Haller DG, Labianca R, Maleux G, Roth A, Ducreux M, Schmiegel W, Seufferlein T, Van Cutsem E.

Dig Liver Dis. 2016 Oct;48(10):1119-23. doi: 10.1016/j.dld.2016.06.009. Epub 2016 Jun 17. Review.

PMID:
27375207
46.

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer.

Lutz MP, Zalcberg JR, Glynne-Jones R, Ruers T, Ducreux M, Arnold D, Aust D, Brown G, Bujko K, Cunningham C, Evrard S, Folprecht G, Gerard JP, Habr-Gama A, Haustermans K, Holm T, Kuhlmann KF, Lordick F, Mentha G, Moehler M, Nagtegaal ID, Pigazzi A, Pucciarelli S, Roth A, Rutten H, Schmoll HJ, Sorbye H, Van Cutsem E, Weitz J, Otto F.

Eur J Cancer. 2016 Aug;63:11-24. doi: 10.1016/j.ejca.2016.04.010. Epub 2016 May 30. Erratum in: Eur J Cancer. 2016 Nov;68:208-209.

47.

Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study.

Berdelou A, Boige V, Arfi-Rouche J, Malka D, Ederhy S, Izzedine H, Leboulleux S, Chougnet CN, Burtin P, De Baere T, Laplanche A, Elias D, Schlumberger M, Scoazec JY, Ducreux M, Baudin E.

Neuroendocrinology. 2017;105(1):26-34. doi: 10.1159/000446988. Epub 2016 May 26.

48.

Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.

Walter T, Planchard D, Bouledrak K, Scoazec JY, Souquet PJ, Dussol AS, Guigay J, Hervieu V, Berdelou A, Ducreux M, Arpin D, Lombard-Bohas C, Baudin E.

Lung Cancer. 2016 Jun;96:68-73. doi: 10.1016/j.lungcan.2016.03.018. Epub 2016 Mar 31.

PMID:
27133753
49.

Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.

Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Alsina Maqueda M, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M.

Eur J Cancer. 2016 May;59:160-170. doi: 10.1016/j.ejca.2016.02.020. Epub 2016 Mar 31. Review.

PMID:
27039171
50.

Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial.

Król A, Ferrer L, Pignon JP, Proust-Lima C, Ducreux M, Bouché O, Michiels S, Rondeau V.

Biometrics. 2016 Sep;72(3):907-16. doi: 10.1111/biom.12490. Epub 2016 Feb 17.

PMID:
26890381

Supplemental Content

Loading ...
Support Center